Sepracor: Why Won't Companies Buy Low-Risk Research?

In an industry crying out for ways to save their genericizing drugs, Sepracor offers a solution-but only one company has taken them up on their offer. The problem has more to do with the culture of pharmaceutical R&D than with economics.